SciSparc Ltd. Stock

Equities

SPRC

IL0010951403

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-05-22 pm EDT 5-day change 1st Jan Change
1.17 USD -0.85% Intraday chart for SciSparc Ltd. -2.50% -76.02%
Sales 2022 1.35 Sales 2023 2.88 Capitalization 2.56M
Net income 2022 -2M Net income 2023 -5M EV / Sales 2022 1,145,812 x
Net cash position 2022 3.55M Net cash position 2023 5M EV / Sales 2023 -848,893 x
P/E ratio 2022
-1.33 x
P/E ratio 2023
-0.34 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 99.98%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.85%
1 week-2.50%
Current month-16.43%
1 month-4.10%
3 months-69.69%
6 months-84.27%
Current year-76.02%
More quotes
1 week
1.16
Extreme 1.16
1.24
1 month
1.16
Extreme 1.16
1.44
Current year
1.15
Extreme 1.15
6.78
1 year
1.15
Extreme 1.15
23.66
3 years
0.00
Extreme 0.0026
221.00
5 years
0.00
Extreme 0.0026
221.00
10 years
0.00
Extreme 0.0026
221.00
More quotes
Date Price Change Volume
24-05-22 1.17 -0.85% 26,593
24-05-21 1.18 -3.28% 40,077
24-05-20 1.22 0.00% 35,657
24-05-17 1.22 +1.67% 54,132
24-05-16 1.2 0.00% 106,538

Delayed Quote Nasdaq, May 22, 2024 at 04:30 pm EDT

More quotes
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
More about the company

Annual profits - Rate of surprise